First-Line Osimertinib Plus Chemo Approved in Japan for EGFR+ Advanced NSCLC
First-line osimertinib (Tagrisso) plus pemetrexed and platinum-based chemotherapy has been approved by the Japanese Pharmaceuticals and Medical Device Agency (PMDA) for the treatment of adult patients with locally advanced or metastatic non–small cell lung …